Literature DB >> 25319226

[Interstitial lung diseases. The pattern is important].

L Fink1.   

Abstract

Interstitial lung diseases (ILDs) comprise a number of rare entities with an estimated incidence of 10-25 per 100,000 inhabitants but the incidence greatly increases beyond the age of 65 years. The prognosis depends on the underlying cause. The fibrotic disorders show a set of radiological and histopathological patterns that are distinct but not entirely specific. In the absence of a clear clinical picture and consistent high resolution computed tomography (HRCT) findings, patients are advised to undergo surgical lung biopsies from two or three lung lobes (or transbronchial biopsies) to determine the histopathological pattern. The ILDs are differentiated into disorders of known causes (e.g. collagen vascular disease, drug-related), idiopathic interstitial pneumonia (IIP), granulomatous ILDs (e.g. sarcoidosis) and other forms of ILD (e.g. Langerhans' cell histiocytosis). The IIPs encompass idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis-interstitial lung disease, cryptogen organizing pneumonia, lymphocytic interstitial pneumonia and acute interstitial pneumonia. Additionally, a category of unclassified interstitial pneumonia exists. The pathologist has to recognize and address the histopathological pattern. In a multidisciplinary discussion the disorder is allocated to a clinicopathological entity and the histopathological pattern plays a major role in the classification of the entity. Recognition of the underlying pattern and the respective histopathological differential diagnoses is important as the therapy varies depending on the cause and ranges from elimination of the stimulus (if possible) to antifibrotic drug therapy up to preparation for lung transplantation.

Entities:  

Mesh:

Year:  2014        PMID: 25319226     DOI: 10.1007/s00292-014-1923-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  17 in total

1.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

2.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors:  Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2011-05-13       Impact factor: 79.321

Review 3.  Smoking-related interstitial fibrosis (SRIF), pathogenesis and treatment of usual interstitial pneumonia (UIP), and transbronchial biopsy in UIP.

Authors:  Anna-Luise A Katzenstein
Journal:  Mod Pathol       Date:  2012-01       Impact factor: 7.842

4.  Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe fibrosis.

Authors:  Kentaro Watanabe; Nobuhiko Nagata; Yasuhiko Kitasato; Kentaro Wakamatsu; Kazuki Nabeshima; Taishi Harada; Takako Hirota; Motokimi Shiraishi; Masaki Fujita
Journal:  Respir Investig       Date:  2012-08-01

5.  The epidemiology of interstitial lung diseases.

Authors:  D B Coultas; R E Zumwalt; W C Black; R E Sobonya
Journal:  Am J Respir Crit Care Med       Date:  1994-10       Impact factor: 21.405

6.  [German guideline for diagnosis and management of idiopathic pulmonary fibrosis].

Authors:  J Behr; A Günther; W Ammenwerth; I Bittmann; R Bonnet; R Buhl; O Eickelberg; R Ewert; S Gläser; J Gottlieb; C Grohé; M Kreuter; C Kroegel; P Markart; C Neurohr; M Pfeifer; A Prasse; N Schönfeld; J Schreiber; H Sitter; D Theegarten; A Theile; A Wilke; H Wirtz; C Witt; H Worth; P Zabel; J Müller-Quernheim; U Costabel
Journal:  Pneumologie       Date:  2013-01-16

Review 7.  Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.

Authors:  Luba Nalysnyk; Javier Cid-Ruzafa; Philip Rotella; Dirk Esser
Journal:  Eur Respir Rev       Date:  2012-12-01

8.  Epidemiology of interstitial lung diseases in Greece.

Authors:  A Karakatsani; D Papakosta; A Rapti; K M Antoniou; M Dimadi; A Markopoulou; P Latsi; V Polychronopoulos; G Birba; Labrakis Ch; D Bouros
Journal:  Respir Med       Date:  2009-04-03       Impact factor: 3.415

9.  Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases.

Authors:  Gian Luca Casoni; Sara Tomassetti; Alberto Cavazza; Thomas V Colby; Alessandra Dubini; Jay H Ryu; Elisa Carretta; Paola Tantalocco; Sara Piciucchi; Claudia Ravaglia; Christian Gurioli; Micaela Romagnoli; Carlo Gurioli; Marco Chilosi; Venerino Poletti
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

Review 10.  Interstitial lung diseases-can pathologists arrive at an etiology-based diagnosis? A critical update.

Authors:  Helmut H Popper
Journal:  Virchows Arch       Date:  2012-12-07       Impact factor: 4.064

View more
  1 in total

1.  [Chronic fibrosing lung diseases : Idiopathic pulmonary fibrosis from the perspective of its differential diagnosis].

Authors:  R C Dartsch; L Fink; A Breithecker; P Markart; S Tello; W Seeger; A Günther
Journal:  Internist (Berl)       Date:  2019-04       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.